LaFleur & Godfrey LLC lowered its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 14.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,136 shares of the healthcare product maker’s stock after selling 11,070 shares during the quarter. LaFleur & Godfrey LLC’s holdings in Abbott Laboratories were worth $6,536,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. BlackRock Inc. grew its position in Abbott Laboratories by 4.6% during the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares in the last quarter. State Street Corp raised its stake in Abbott Laboratories by 1.7% during the 2nd quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after purchasing an additional 1,350,766 shares during the period. Bank of America Corp DE purchased a new stake in shares of Abbott Laboratories in the second quarter valued at $1,603,607,000. Deutsche Bank AG lifted its holdings in shares of Abbott Laboratories by 18.6% in the second quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker’s stock valued at $1,515,963,000 after purchasing an additional 2,614,965 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of Abbott Laboratories in the second quarter worth $1,082,524,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Trending Headlines about Abbott Laboratories
Here are the key news stories impacting Abbott Laboratories this week:
- Positive Sentiment: Abbott launched a next-generation Oncodetect test designed to detect residual cancer disease, expanding its diagnostics portfolio and potentially supporting longer-term growth in oncology testing. Abbott Launches Next-Generation Oncodetect Test
- Positive Sentiment: The planned spin-off of Abbott’s Nutrition segment, which generates approximately $8.5 billion in annual sales, could allow the remaining company and the new standalone business to pursue more focused strategies. Abbott has appointed Daniel Salvadori to lead the future Nutrition company. What Could Abbott Laboratories Spin Off Mean for Its Future Growth?
- Positive Sentiment: Abbott received approximately $23.9 million in net ETF buying, indicating some continued institutional demand for ABT shares despite recent volatility. Abbott Sees $23.9 Million in Net ETF Buying
- Neutral Sentiment: Abbott is included in coverage of Europe’s medical foods market, which is projected to grow from $6.5 billion in 2026 to $7.9 billion by 2033. The outlook highlights a long-term opportunity for Abbott’s specialized nutrition business, though it does not represent new company-specific revenue. Europe Medical Foods Market Strategic Outlook
- Negative Sentiment: Argus Research downgraded Abbott from “Buy” to “Hold,” reportedly citing a guidance cut. The change removes a bullish rating catalyst and reinforces investor concerns about near-term demand and earnings visibility. Abbott Downgraded at Argus on Guidance Cut
- Negative Sentiment: Higher interest-rate expectations are creating pressure on richly valued quality-growth stocks such as Abbott, as elevated rates can reduce the value investors assign to future earnings. Demand headwinds and litigation risks are also cited as concerns. Abbott Demand Headwinds and Litigation Risks
Abbott Laboratories Stock Down 0.4%
ABT stock opened at $102.66 on Thursday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $132.02. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company has a market cap of $177.64 billion, a price-to-earnings ratio of 38.31, a PEG ratio of 1.82 and a beta of 0.59. The company has a 50 day moving average of $104.72 and a two-hundred day moving average of $102.26.
Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.42. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The company had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. During the same quarter last year, the business posted $1.30 EPS. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. On average, equities analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.
Abbott Laboratories Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 94.03%.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on ABT shares. Wells Fargo & Company lifted their price target on Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a report on Thursday, October 22nd. Wall Street Zen raised Abbott Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, October 24th. UBS Group decreased their price objective on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating for the company in a research report on Tuesday, July 28th. Robert W. Baird raised their price objective on Abbott Laboratories from $121.00 to $123.00 and gave the stock an “outperform” rating in a research report on Thursday, October 22nd. Finally, Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price on the stock in a research note on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.32.
View Our Latest Research Report on Abbott Laboratories
Abbott Laboratories Profile
Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.
Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.
The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.
Read More
- Five stocks we like better than Abbott Laboratories
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
